Industry Research Reports

Home > Reports > Medical Care > Cancer Therapeutics and Biotherapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Cancer Therapeutics and Biotherapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Industry: Medical Care

Published: 2024-01-24

Pages: 86 Pages

Report ld: 2333293

Description
Table of Contents
Table of Figures
PDF Download

Description
Table of Contents
Table of Figures
PDF Download

Description

The global market for Cancer Therapeutics and Biotherapeutics was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Cancer Therapeutics and Biotherapeutics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Cancer Therapeutics and Biotherapeutics by region & country, by Type, and by Application.

The Cancer Therapeutics and Biotherapeutics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Therapeutics and Biotherapeutics.

Market Segmentation

Report Metric
Details
Report Title
Cancer Therapeutics and Biotherapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Global Cancer Therapeutics and Biotherapeutics Companies Covered
AstraZeneca, Bristol-Myers Squibb, Eli Lilly & Company, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi
Global Cancer Therapeutics and Biotherapeutics Market, by Region
North America (U.S., Canada, Mexico)

Europe (Germany, France, UK, Italy, etc.)

Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)

South America (Brazil, etc.)

Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Cancer Therapeutics and Biotherapeutics Market, Segment by Type
Chemotherapy

Radiation Therapy

Hormone Therapy

Biotherapy

Others
Global Cancer Therapeutics and Biotherapeutics Market, Segment by Application
Household

Hospital
Forecast Units
USD million in value
Report Coverage
Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Cancer Therapeutics and Biotherapeutics manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Cancer Therapeutics and Biotherapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Cancer Therapeutics and Biotherapeutics in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Table of Contents

 1 Market Overview
    1.1 Cancer Therapeutics and Biotherapeutics Product Introduction
    1.2 Global Cancer Therapeutics and Biotherapeutics Market Size Forecast
    1.3 Cancer Therapeutics and Biotherapeutics Market Trends & Drivers
        1.3.1 Cancer Therapeutics and Biotherapeutics Industry Trends
        1.3.2 Cancer Therapeutics and Biotherapeutics Market Drivers & Opportunity
        1.3.3 Cancer Therapeutics and Biotherapeutics Market Challenges
        1.3.4 Cancer Therapeutics and Biotherapeutics Market Restraints
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered

 2 Competitive Analysis by Company
    2.1 Global Cancer Therapeutics and Biotherapeutics Players Revenue Ranking (2023)
    2.2 Global Cancer Therapeutics and Biotherapeutics Revenue by Company (2019-2024)
    2.3 Key Companies Cancer Therapeutics and Biotherapeutics Manufacturing Base Distribution and Headquarters
    2.4 Key Companies Cancer Therapeutics and Biotherapeutics Product Offered
    2.5 Key Companies Time to Begin Mass Production of Cancer Therapeutics and Biotherapeutics
    2.6 Cancer Therapeutics and Biotherapeutics Market Competitive Analysis
        2.6.1 Cancer Therapeutics and Biotherapeutics Market Concentration Rate (2019-2024)
        2.6.2 Global 5 and 10 Largest Companies by Cancer Therapeutics and Biotherapeutics Revenue in 2023
        2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Therapeutics and Biotherapeutics as of 2023)
    2.7 Mergers & Acquisitions, Expansion

 3 Segmentation by Type
    3.1 Introduction by Type
        3.1.1 Chemotherapy
        3.1.2 Radiation Therapy
        3.1.3 Hormone Therapy
        3.1.4 Biotherapy
        3.1.5 Others
    3.2 Global Cancer Therapeutics and Biotherapeutics Sales Value by Type
        3.2.1 Global Cancer Therapeutics and Biotherapeutics Sales Value by Type (2019 VS 2023 VS 2030)
        3.2.2 Global Cancer Therapeutics and Biotherapeutics Sales Value, by Type (2019-2030)
        3.2.3 Global Cancer Therapeutics and Biotherapeutics Sales Value, by Type (%) (2019-2030)

 4 Segmentation by Application
    4.1 Introduction by Application
        4.1.1 Household
        4.1.2 Hospital
    4.2 Global Cancer Therapeutics and Biotherapeutics Sales Value by Application
        4.2.1 Global Cancer Therapeutics and Biotherapeutics Sales Value by Application (2019 VS 2023 VS 2030)
        4.2.2 Global Cancer Therapeutics and Biotherapeutics Sales Value, by Application (2019-2030)
        4.2.3 Global Cancer Therapeutics and Biotherapeutics Sales Value, by Application (%) (2019-2030)

 5 Segmentation by Region
    5.1 Global Cancer Therapeutics and Biotherapeutics Sales Value by Region
        5.1.1 Global Cancer Therapeutics and Biotherapeutics Sales Value by Region: 2019 VS 2023 VS 2030
        5.1.2 Global Cancer Therapeutics and Biotherapeutics Sales Value by Region (2019-2024)
        5.1.3 Global Cancer Therapeutics and Biotherapeutics Sales Value by Region (2025-2030)
        5.1.4 Global Cancer Therapeutics and Biotherapeutics Sales Value by Region (%), (2019-2030)
    5.2 North America
        5.2.1 North America Cancer Therapeutics and Biotherapeutics Sales Value, 2019-2030
        5.2.2 North America Cancer Therapeutics and Biotherapeutics Sales Value by Country (%), 2023 VS 2030
    5.3 Europe
        5.3.1 Europe Cancer Therapeutics and Biotherapeutics Sales Value, 2019-2030
        5.3.2 Europe Cancer Therapeutics and Biotherapeutics Sales Value by Country (%), 2023 VS 2030
    5.4 Asia Pacific
        5.4.1 Asia Pacific Cancer Therapeutics and Biotherapeutics Sales Value, 2019-2030
        5.4.2 Asia Pacific Cancer Therapeutics and Biotherapeutics Sales Value by Country (%), 2023 VS 2030
    5.5 South America
        5.5.1 South America Cancer Therapeutics and Biotherapeutics Sales Value, 2019-2030
        5.5.2 South America Cancer Therapeutics and Biotherapeutics Sales Value by Country (%), 2023 VS 2030
    5.6 Middle East & Africa
        5.6.1 Middle East & Africa Cancer Therapeutics and Biotherapeutics Sales Value, 2019-2030
        5.6.2 Middle East & Africa Cancer Therapeutics and Biotherapeutics Sales Value by Country (%), 2023 VS 2030

 6 Segmentation by Key Countries/Regions
    6.1 Key Countries/Regions Cancer Therapeutics and Biotherapeutics Sales Value Growth Trends, 2019 VS 2023 VS 2030
    6.2 Key Countries/Regions Cancer Therapeutics and Biotherapeutics Sales Value
    6.3 United States
        6.3.1 United States Cancer Therapeutics and Biotherapeutics Sales Value, 2019-2030
        6.3.2 United States Cancer Therapeutics and Biotherapeutics Sales Value by Type (%), 2023 VS 2030
        6.3.3 United States Cancer Therapeutics and Biotherapeutics Sales Value by Application, 2023 VS 2030
    6.4 Europe
        6.4.1 Europe Cancer Therapeutics and Biotherapeutics Sales Value, 2019-2030
        6.4.2 Europe Cancer Therapeutics and Biotherapeutics Sales Value by Type (%), 2023 VS 2030
        6.4.3 Europe Cancer Therapeutics and Biotherapeutics Sales Value by Application, 2023 VS 2030
    6.5 China
        6.5.1 China Cancer Therapeutics and Biotherapeutics Sales Value, 2019-2030
        6.5.2 China Cancer Therapeutics and Biotherapeutics Sales Value by Type (%), 2023 VS 2030
        6.5.3 China Cancer Therapeutics and Biotherapeutics Sales Value by Application, 2023 VS 2030
    6.6 Japan
        6.6.1 Japan Cancer Therapeutics and Biotherapeutics Sales Value, 2019-2030
        6.6.2 Japan Cancer Therapeutics and Biotherapeutics Sales Value by Type (%), 2023 VS 2030
        6.6.3 Japan Cancer Therapeutics and Biotherapeutics Sales Value by Application, 2023 VS 2030
    6.7 South Korea
        6.7.1 South Korea Cancer Therapeutics and Biotherapeutics Sales Value, 2019-2030
        6.7.2 South Korea Cancer Therapeutics and Biotherapeutics Sales Value by Type (%), 2023 VS 2030
        6.7.3 South Korea Cancer Therapeutics and Biotherapeutics Sales Value by Application, 2023 VS 2030
    6.8 Southeast Asia
        6.8.1 Southeast Asia Cancer Therapeutics and Biotherapeutics Sales Value, 2019-2030
        6.8.2 Southeast Asia Cancer Therapeutics and Biotherapeutics Sales Value by Type (%), 2023 VS 2030
        6.8.3 Southeast Asia Cancer Therapeutics and Biotherapeutics Sales Value by Application, 2023 VS 2030
    6.9 India
        6.9.1 India Cancer Therapeutics and Biotherapeutics Sales Value, 2019-2030
        6.9.2 India Cancer Therapeutics and Biotherapeutics Sales Value by Type (%), 2023 VS 2030
        6.9.3 India Cancer Therapeutics and Biotherapeutics Sales Value by Application, 2023 VS 2030

 7 Company Profiles
    7.1 AstraZeneca
        7.1.1 AstraZeneca Profile
        7.1.2 AstraZeneca Main Business
        7.1.3 AstraZeneca Cancer Therapeutics and Biotherapeutics Products, Services and Solutions
        7.1.4 AstraZeneca Cancer Therapeutics and Biotherapeutics Revenue (US$ Million) & (2019-2024)
        7.1.5 AstraZeneca Recent Developments
    7.2 Bristol-Myers Squibb
        7.2.1 Bristol-Myers Squibb Profile
        7.2.2 Bristol-Myers Squibb Main Business
        7.2.3 Bristol-Myers Squibb Cancer Therapeutics and Biotherapeutics Products, Services and Solutions
        7.2.4 Bristol-Myers Squibb Cancer Therapeutics and Biotherapeutics Revenue (US$ Million) & (2019-2024)
        7.2.5 Bristol-Myers Squibb Recent Developments
    7.3 Eli Lilly & Company
        7.3.1 Eli Lilly & Company Profile
        7.3.2 Eli Lilly & Company Main Business
        7.3.3 Eli Lilly & Company Cancer Therapeutics and Biotherapeutics Products, Services and Solutions
        7.3.4 Eli Lilly & Company Cancer Therapeutics and Biotherapeutics Revenue (US$ Million) & (2019-2024)
        7.3.5 Johnson & Johnson Recent Developments
    7.4 Johnson & Johnson
        7.4.1 Johnson & Johnson Profile
        7.4.2 Johnson & Johnson Main Business
        7.4.3 Johnson & Johnson Cancer Therapeutics and Biotherapeutics Products, Services and Solutions
        7.4.4 Johnson & Johnson Cancer Therapeutics and Biotherapeutics Revenue (US$ Million) & (2019-2024)
        7.4.5 Johnson & Johnson Recent Developments
    7.5 Merck
        7.5.1 Merck Profile
        7.5.2 Merck Main Business
        7.5.3 Merck Cancer Therapeutics and Biotherapeutics Products, Services and Solutions
        7.5.4 Merck Cancer Therapeutics and Biotherapeutics Revenue (US$ Million) & (2019-2024)
        7.5.5 Merck Recent Developments
    7.6 Novartis
        7.6.1 Novartis Profile
        7.6.2 Novartis Main Business
        7.6.3 Novartis Cancer Therapeutics and Biotherapeutics Products, Services and Solutions
        7.6.4 Novartis Cancer Therapeutics and Biotherapeutics Revenue (US$ Million) & (2019-2024)
        7.6.5 Novartis Recent Developments
    7.7 Pfizer
        7.7.1 Pfizer Profile
        7.7.2 Pfizer Main Business
        7.7.3 Pfizer Cancer Therapeutics and Biotherapeutics Products, Services and Solutions
        7.7.4 Pfizer Cancer Therapeutics and Biotherapeutics Revenue (US$ Million) & (2019-2024)
        7.7.5 Pfizer Recent Developments
    7.8 Roche
        7.8.1 Roche Profile
        7.8.2 Roche Main Business
        7.8.3 Roche Cancer Therapeutics and Biotherapeutics Products, Services and Solutions
        7.8.4 Roche Cancer Therapeutics and Biotherapeutics Revenue (US$ Million) & (2019-2024)
        7.8.5 Roche Recent Developments
    7.9 Sanofi
        7.9.1 Sanofi Profile
        7.9.2 Sanofi Main Business
        7.9.3 Sanofi Cancer Therapeutics and Biotherapeutics Products, Services and Solutions
        7.9.4 Sanofi Cancer Therapeutics and Biotherapeutics Revenue (US$ Million) & (2019-2024)
        7.9.5 Sanofi Recent Developments

 8 Industry Chain Analysis
    8.1 Cancer Therapeutics and Biotherapeutics Industrial Chain
    8.2 Cancer Therapeutics and Biotherapeutics Upstream Analysis
        8.2.1 Key Raw Materials
        8.2.2 Raw Materials Key Suppliers
        8.2.3 Manufacturing Cost Structure
    8.3 Midstream Analysis
    8.4 Downstream Analysis (Customers Analysis)
    8.5 Sales Model and Sales Channels
        8.5.1 Cancer Therapeutics and Biotherapeutics Sales Model
        8.5.2 Sales Channel
        8.5.3 Cancer Therapeutics and Biotherapeutics Distributors

 9 Research Findings and Conclusion

 10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
        10.1.2 Data Source
    10.2 Author Details
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Cancer Therapeutics and Biotherapeutics Market Trends
    Table 2. Cancer Therapeutics and Biotherapeutics Market Drivers & Opportunity
    Table 3. Cancer Therapeutics and Biotherapeutics Market Challenges
    Table 4. Cancer Therapeutics and Biotherapeutics Market Restraints
    Table 5. Global Cancer Therapeutics and Biotherapeutics Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Cancer Therapeutics and Biotherapeutics Revenue Market Share by Company (2019-2024)
    Table 7. Key Companies Cancer Therapeutics and Biotherapeutics Manufacturing Base Distribution and Headquarters
    Table 8. Key Companies Cancer Therapeutics and Biotherapeutics Product Type
    Table 9. Key Companies Time to Begin Mass Production of Cancer Therapeutics and Biotherapeutics
    Table 10. Global Cancer Therapeutics and Biotherapeutics Companies Market Concentration Ratio (CR5 and HHI)
    Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Therapeutics and Biotherapeutics as of 2023)
    Table 12. Mergers & Acquisitions, Expansion Plans
    Table 13. Global Cancer Therapeutics and Biotherapeutics Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 14. Global Cancer Therapeutics and Biotherapeutics Sales Value by Type (2019-2024) & (US$ Million)
    Table 15. Global Cancer Therapeutics and Biotherapeutics Sales Value by Type (2025-2030) & (US$ Million)
    Table 16. Global Cancer Therapeutics and Biotherapeutics Sales Market Share in Value by Type (2019-2024) & (%)
    Table 17. Global Cancer Therapeutics and Biotherapeutics Sales Market Share in Value by Type (2025-2030) & (%)
    Table 18. Global Cancer Therapeutics and Biotherapeutics Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 19. Global Cancer Therapeutics and Biotherapeutics Sales Value by Application (2019-2024) & (US$ Million)
    Table 20. Global Cancer Therapeutics and Biotherapeutics Sales Value by Application (2025-2030) & (US$ Million)
    Table 21. Global Cancer Therapeutics and Biotherapeutics Sales Market Share in Value by Application (2019-2024) & (%)
    Table 22. Global Cancer Therapeutics and Biotherapeutics Sales Market Share in Value by Application (2025-2030) & (%)
    Table 23. Global Cancer Therapeutics and Biotherapeutics Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 24. Global Cancer Therapeutics and Biotherapeutics Sales Value by Region (2019-2024) & (US$ Million)
    Table 25. Global Cancer Therapeutics and Biotherapeutics Sales Value by Region (2025-2030) & (US$ Million)
    Table 26. Global Cancer Therapeutics and Biotherapeutics Sales Value by Region (2019-2024) & (%)
    Table 27. Global Cancer Therapeutics and Biotherapeutics Sales Value by Region (2025-2030) & (%)
    Table 28. Key Countries/Regions Cancer Therapeutics and Biotherapeutics Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 29. Key Countries/Regions Cancer Therapeutics and Biotherapeutics Sales Value, (2019-2024) & (US$ Million)
    Table 30. Key Countries/Regions Cancer Therapeutics and Biotherapeutics Sales Value, (2025-2030) & (US$ Million)
    Table 31. AstraZeneca Basic Information List
    Table 32. AstraZeneca Description and Business Overview
    Table 33. AstraZeneca Cancer Therapeutics and Biotherapeutics Products, Services and Solutions
    Table 34. Revenue (US$ Million) in Cancer Therapeutics and Biotherapeutics Business of AstraZeneca (2019-2024)
    Table 35. AstraZeneca Recent Developments
    Table 36. Bristol-Myers Squibb Basic Information List
    Table 37. Bristol-Myers Squibb Description and Business Overview
    Table 38. Bristol-Myers Squibb Cancer Therapeutics and Biotherapeutics Products, Services and Solutions
    Table 39. Revenue (US$ Million) in Cancer Therapeutics and Biotherapeutics Business of Bristol-Myers Squibb (2019-2024)
    Table 40. Bristol-Myers Squibb Recent Developments
    Table 41. Eli Lilly & Company Basic Information List
    Table 42. Eli Lilly & Company Description and Business Overview
    Table 43. Eli Lilly & Company Cancer Therapeutics and Biotherapeutics Products, Services and Solutions
    Table 44. Revenue (US$ Million) in Cancer Therapeutics and Biotherapeutics Business of Eli Lilly & Company (2019-2024)
    Table 45. Eli Lilly & Company Recent Developments
    Table 46. Johnson & Johnson Basic Information List
    Table 47. Johnson & Johnson Description and Business Overview
    Table 48. Johnson & Johnson Cancer Therapeutics and Biotherapeutics Products, Services and Solutions
    Table 49. Revenue (US$ Million) in Cancer Therapeutics and Biotherapeutics Business of Johnson & Johnson (2019-2024)
    Table 50. Johnson & Johnson Recent Developments
    Table 51. Merck Basic Information List
    Table 52. Merck Description and Business Overview
    Table 53. Merck Cancer Therapeutics and Biotherapeutics Products, Services and Solutions
    Table 54. Revenue (US$ Million) in Cancer Therapeutics and Biotherapeutics Business of Merck (2019-2024)
    Table 55. Merck Recent Developments
    Table 56. Novartis Basic Information List
    Table 57. Novartis Description and Business Overview
    Table 58. Novartis Cancer Therapeutics and Biotherapeutics Products, Services and Solutions
    Table 59. Revenue (US$ Million) in Cancer Therapeutics and Biotherapeutics Business of Novartis (2019-2024)
    Table 60. Novartis Recent Developments
    Table 61. Pfizer Basic Information List
    Table 62. Pfizer Description and Business Overview
    Table 63. Pfizer Cancer Therapeutics and Biotherapeutics Products, Services and Solutions
    Table 64. Revenue (US$ Million) in Cancer Therapeutics and Biotherapeutics Business of Pfizer (2019-2024)
    Table 65. Pfizer Recent Developments
    Table 66. Roche Basic Information List
    Table 67. Roche Description and Business Overview
    Table 68. Roche Cancer Therapeutics and Biotherapeutics Products, Services and Solutions
    Table 69. Revenue (US$ Million) in Cancer Therapeutics and Biotherapeutics Business of Roche (2019-2024)
    Table 70. Roche Recent Developments
    Table 71. Sanofi Basic Information List
    Table 72. Sanofi Description and Business Overview
    Table 73. Sanofi Cancer Therapeutics and Biotherapeutics Products, Services and Solutions
    Table 74. Revenue (US$ Million) in Cancer Therapeutics and Biotherapeutics Business of Sanofi (2019-2024)
    Table 75. Sanofi Recent Developments
    Table 76. Key Raw Materials Lists
    Table 77. Raw Materials Key Suppliers Lists
    Table 78. Cancer Therapeutics and Biotherapeutics Downstream Customers
    Table 79. Cancer Therapeutics and Biotherapeutics Distributors List
    Table 80. Research Programs/Design for This Report
    Table 81. Key Data Information from Secondary Sources
    Table 82. Key Data Information from Primary Sources
    Table 83. Business Unit and Senior & Team Lead Analysts
List of Figures
    Figure 1. Cancer Therapeutics and Biotherapeutics Product Picture
    Figure 2. Global Cancer Therapeutics and Biotherapeutics Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Cancer Therapeutics and Biotherapeutics Sales Value (2019-2030) & (US$ Million)
    Figure 4. Cancer Therapeutics and Biotherapeutics Report Years Considered
    Figure 5. Global Cancer Therapeutics and Biotherapeutics Players Revenue Ranking (2023) & (US$ Million)
    Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Cancer Therapeutics and Biotherapeutics Revenue in 2023
    Figure 7. Cancer Therapeutics and Biotherapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 8. Chemotherapy Picture
    Figure 9. Radiation Therapy Picture
    Figure 10. Hormone Therapy Picture
    Figure 11. Biotherapy Picture
    Figure 12. Others Picture
    Figure 13. Global Cancer Therapeutics and Biotherapeutics Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 14. Global Cancer Therapeutics and Biotherapeutics Sales Value Market Share by Type, 2023 & 2030
    Figure 15. Product Picture of Household
    Figure 16. Product Picture of Hospital
    Figure 17. Global Cancer Therapeutics and Biotherapeutics Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 18. Global Cancer Therapeutics and Biotherapeutics Sales Value Market Share by Application, 2023 & 2030
    Figure 19. North America Cancer Therapeutics and Biotherapeutics Sales Value (2019-2030) & (US$ Million)
    Figure 20. North America Cancer Therapeutics and Biotherapeutics Sales Value by Country (%), 2023 VS 2030
    Figure 21. Europe Cancer Therapeutics and Biotherapeutics Sales Value (2019-2030) & (US$ Million)
    Figure 22. Europe Cancer Therapeutics and Biotherapeutics Sales Value by Country (%), 2023 VS 2030
    Figure 23. Asia Pacific Cancer Therapeutics and Biotherapeutics Sales Value (2019-2030) & (US$ Million)
    Figure 24. Asia Pacific Cancer Therapeutics and Biotherapeutics Sales Value by Country (%), 2023 VS 2030
    Figure 25. South America Cancer Therapeutics and Biotherapeutics Sales Value (2019-2030) & (US$ Million)
    Figure 26. South America Cancer Therapeutics and Biotherapeutics Sales Value by Country (%), 2023 VS 2030
    Figure 27. Middle East & Africa Cancer Therapeutics and Biotherapeutics Sales Value (2019-2030) & (US$ Million)
    Figure 28. Middle East & Africa Cancer Therapeutics and Biotherapeutics Sales Value by Country (%), 2023 VS 2030
    Figure 29. Key Countries/Regions Cancer Therapeutics and Biotherapeutics Sales Value (%), (2019-2030)
    Figure 30. United States Cancer Therapeutics and Biotherapeutics Sales Value, (2019-2030) & (US$ Million)
    Figure 31. United States Cancer Therapeutics and Biotherapeutics Sales Value by Type (%), 2023 VS 2030
    Figure 32. United States Cancer Therapeutics and Biotherapeutics Sales Value by Application (%), 2023 VS 2030
    Figure 33. Europe Cancer Therapeutics and Biotherapeutics Sales Value, (2019-2030) & (US$ Million)
    Figure 34. Europe Cancer Therapeutics and Biotherapeutics Sales Value by Type (%), 2023 VS 2030
    Figure 35. Europe Cancer Therapeutics and Biotherapeutics Sales Value by Application (%), 2023 VS 2030
    Figure 36. China Cancer Therapeutics and Biotherapeutics Sales Value, (2019-2030) & (US$ Million)
    Figure 37. China Cancer Therapeutics and Biotherapeutics Sales Value by Type (%), 2023 VS 2030
    Figure 38. China Cancer Therapeutics and Biotherapeutics Sales Value by Application (%), 2023 VS 2030
    Figure 39. Japan Cancer Therapeutics and Biotherapeutics Sales Value, (2019-2030) & (US$ Million)
    Figure 40. Japan Cancer Therapeutics and Biotherapeutics Sales Value by Type (%), 2023 VS 2030
    Figure 41. Japan Cancer Therapeutics and Biotherapeutics Sales Value by Application (%), 2023 VS 2030
    Figure 42. South Korea Cancer Therapeutics and Biotherapeutics Sales Value, (2019-2030) & (US$ Million)
    Figure 43. South Korea Cancer Therapeutics and Biotherapeutics Sales Value by Type (%), 2023 VS 2030
    Figure 44. South Korea Cancer Therapeutics and Biotherapeutics Sales Value by Application (%), 2023 VS 2030
    Figure 45. Southeast Asia Cancer Therapeutics and Biotherapeutics Sales Value, (2019-2030) & (US$ Million)
    Figure 46. Southeast Asia Cancer Therapeutics and Biotherapeutics Sales Value by Type (%), 2023 VS 2030
    Figure 47. Southeast Asia Cancer Therapeutics and Biotherapeutics Sales Value by Application (%), 2023 VS 2030
    Figure 48. India Cancer Therapeutics and Biotherapeutics Sales Value, (2019-2030) & (US$ Million)
    Figure 49. India Cancer Therapeutics and Biotherapeutics Sales Value by Type (%), 2023 VS 2030
    Figure 50. India Cancer Therapeutics and Biotherapeutics Sales Value by Application (%), 2023 VS 2030
    Figure 51. Cancer Therapeutics and Biotherapeutics Industrial Chain
    Figure 52. Cancer Therapeutics and Biotherapeutics Manufacturing Cost Structure
    Figure 53. Channels of Distribution (Direct Sales, and Distribution)
    Figure 54. Bottom-up and Top-down Approaches for This Report
    Figure 55. Data Triangulation

Description

The global market for Cancer Therapeutics and Biotherapeutics was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Cancer Therapeutics and Biotherapeutics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Cancer Therapeutics and Biotherapeutics by region & country, by Type, and by Application.

The Cancer Therapeutics and Biotherapeutics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Therapeutics and Biotherapeutics.

Market Segmentation